<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03052530</url>
  </required_header>
  <id_info>
    <org_study_id>VP-0714</org_study_id>
    <nct_id>NCT03052530</nct_id>
  </id_info>
  <brief_title>Sapphire II PRO US Clinical Study</brief_title>
  <official_title>Sapphire II PRO - A Prospective, Open Label, Multi-center, Single Arm, Observational Study Designed to Evaluate the Acute Safety and Device Procedural Success of the Sapphire II PRO 1.0 and 1.25 mm PTCA Dilatation Catheters.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OrbusNeich</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>OrbusNeich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, open label, multi-center, single arm, observational study designed to evaluate
      the acute safety and device procedural success of the Sapphire II PRO 1.0 and 1.25 mm PTCA
      dilatation catheters in subjects with stenotic coronary arteries or bypass grafts during
      percutaneous coronary intervention.

      Sixty (60) subjects will be treated at up to 5 U.S. sites with the Sapphire II PRO diameters
      1.0 and 1.25 mm PTCA dilatation catheters to pre-dilate coronary arteries or bypass grafts
      during their index procedure. All subjects will be screened according to the protocol
      inclusion and exclusion criteria and will be followed through hospital discharge.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 5, 2017</start_date>
  <completion_date type="Actual">July 24, 2017</completion_date>
  <primary_completion_date type="Actual">July 24, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Device Procedural Success</measure>
    <time_frame>Peri-procedural (at Day 0)</time_frame>
    <description>Device procedural success consisting of the following:
Successful delivery, inflation, deflation and withdrawal of the study balloon
No evidence of vessel perforation, flow limiting dissection (grade C or higher) or reduction in TIMI flow from baseline related to the study balloon
Final TIMI flow grade of 3 at the conclusion of the PCI procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With In-hospital Major Adverse Cardiac Events (MACE)</measure>
    <time_frame>Endpoints will be measured through hospital discharge (expected to be within 24 hours)</time_frame>
    <description>In-hospital Major Adverse Cardiac Events (MACE)
All death (cardiac and non-cardiac)
Myocardial infarction (MI)
Target Lesion Revascularization (TLR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With In-hospital Stent Thrombosis (ST) Within the Target Vessel</measure>
    <time_frame>Endpoint will be measured through hospital discharge (expected to be within 24 hours)</time_frame>
    <description>In-hospital stent thrombosis (ST) within the target vessel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Arrhythmias (Requiring Intervention)</measure>
    <time_frame>Endpoint will be measured through hospital discharge (expected to be within 24 hours)</time_frame>
    <description>Clinically Significant Arrhythmias (requiring intervention)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Coronary Disease</condition>
  <condition>Myocardial Ischemia</condition>
  <condition>Heart Diseases</condition>
  <condition>Arteriosclerosis</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Sapphire II PRO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arm with investigational Sapphire II PRO 1.0 and 1.25 mm PTCA dilatation catheters</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sapphire II PRO</intervention_name>
    <description>To pre-dilate coronary arteries or bypass grafts during the subject's index procedure with Sapphire II PRO 1.0 and 1.25 PTCA dilatation catheters.</description>
    <arm_group_label>Sapphire II PRO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Clinical Inclusion Criteria:

          1. Subject is ≥ 18 years of age.

          2. Subject or a legally authorized representative must provide written informed consent
             prior to any study related procedures.

          3. Subject must agree not to participate in any other clinical study during
             hospitalization for the index procedure that would interfere with the endpoints of
             this study.

          4. Subjects must have a single or double vessel coronary artery disease and clinical
             evidence of ischemic heart disease, such as stable / unstable angina or silent
             ischemia.

             Angiographic Inclusion Criteria

          5. Subject must have de novo or restenotic lesion(s) in native coronary arteries or
             bypass grafts that are suitable for percutaneous coronary intervention. An embolic
             protection device must be used in all Saphenous venous grafts (SVG) interventions
             performed during the index procedure.

          6. A maximum of two lesions, including at least one target lesion, in up to two coronary
             arteries.

          7. Target and non-target lesions must be located in different coronary arteries or bypass
             grafts.

          8. Target lesion(s) must have a diameter stenosis of ≥70% by visual estimation and may
             include chronic total occlusions (CTO)

          9. Treatment of non-target lesion, if any, must be completed prior to treatment of target
             lesion and must be deemed a clinical angiographic success.

        Clinical Exclusion Criteria:

          1. Subject with a known hypersensitivity or contraindication to aspirin, heparin,
             bivalirudin, anti-platelet medications, or sensitivity to contrast media which cannot
             be adequately pre-medicated.

          2. Subject with known diagnosis of an acute myocardial infarction (AMI) within 72 hours
             prior to index procedure.

          3. Subject with known pregnancy or is nursing. Women of child- bearing potential should
             have a documented negative pregnancy test within 7 days before index procedure.

          4. Planned or actual target lesion treatment with an unapproved device, atherectomy,
             laser, cutting balloon or thrombectomy during the index procedure.

          5. A serum creatinine level &gt; 2.0 mg/dl within seven days prior to index procedure.

          6. Cerebrovascular accident (CVA) within the past 6 months.

          7. Active peptic ulcer or active gastrointestinal (GI) bleeding within the past 6 months.

          8. Subject has a known left ventricular ejection fraction (LVEF) &lt;30% (LVEF may be
             obtained at the time of the index procedure if the value is unknown, if necessary)

             Angiographic Exclusion Criteria

          9. More than two lesions requiring treatment.

         10. Unprotected left main coronary artery disease.(Greater than 50% diameter stenosis)

         11. Coronary artery spasm of the target vessel in the absence of a significant stenosis.

         12. Target lesion with angiographic presence of probable or definite thrombus.

         13. Target lesion involves a bifurcation requiring treatment with more than one stent or
             pre-dilatation of a side branch &gt;2.0 mm in diameter.

         14. Non-target lesion to be treated during the index procedure meets any of the following
             criteria:

               -  Located within a bypass graft (venous or arterial)

               -  Left main location

               -  Chronic total occlusion

               -  Involves a bifurcation (e.g., bifurcations requiring treatment with more than 1
                  stent)

               -  Treatment not deemed a clinical angiographic success
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Kandzari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Piedmont Heart Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Heart Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peninsula Regional Medical Center</name>
      <address>
        <city>Salisbury</city>
        <state>Maryland</state>
        <zip>21801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Christ Hospital Heart and Vascular</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2017</study_first_submitted>
  <study_first_submitted_qc>February 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 14, 2017</study_first_posted>
  <results_first_submitted>March 8, 2018</results_first_submitted>
  <results_first_submitted_qc>March 8, 2018</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 4, 2018</results_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Arteriosclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sapphire II PRO</title>
          <description>Single arm with investigational Sapphire II PRO 1.0 and 1.25 mm PTCA dilatation catheters
Sapphire II PRO: To pre-dilate coronary arteries or bypass grafts during the subject's index procedure with Sapphire II PRO 1.0 and 1.25 PTCA dilatation catheters.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sapphire II PRO</title>
          <description>Single arm with investigational Sapphire II PRO 1.0 and 1.25 mm PTCA dilatation catheters</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="61"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.26" spread="9.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cardiac History</title>
          <description>More than one Cardiac History measure may be reported for each participant.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Previous Percutaneous Coronary Intervention</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Previous Coronary Artery Bypass Graft</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Previous Myocardial Infarction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Angina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unstable Angina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cardiac Risk Factors</title>
          <description>More than one Cardiac Risk Factor may be reported for each participant.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Current Cigarette Smoking (within 30 days)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medically Treated Diabetes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypercholesterolemia Requiring Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypertension Requiring Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lesion Characteristics: Vessel Treated</title>
          <description>Analysis is based on the number of intent-to-treat lesions (n=67).</description>
          <units>Lesions</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Bypass Graft</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diagonol Branch-Left Anterior Descending Artery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Anterior Descending Artery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Circumflex Artery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Marginal Branch of Left Circumflex Artery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Posterior Descending Branch-Right Coronary Artery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Coronary Artery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lesion Characteristics: Lesion Location</title>
          <description>Analysis is based on the number of intent-to-treat lesions (n=67).</description>
          <units>Lesions</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Distal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ostial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prox</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lesion Characteristics</title>
          <description>Analysis is based on the number of intent-to-treat lesions (n=67).</description>
          <units>Millimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Lesion Length</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18.42" spread="12.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimum Lumen Diameter</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value=".52" spread=".35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lesion Characteristics</title>
          <description>Analysis is based on the number of intent-to-treat lesions (n=67).</description>
          <units>Lesions</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Thrombus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tortuosity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcification</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ulceration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aneurysm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Occlusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lesion Characteristics: Pre-Procedure Thrombolysis in Myocardial Infarction (TIMI) Flow</title>
          <description>Analysis is based on the number of intent-to-treat lesions (n=67).</description>
          <units>Lesions</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0 (no perfusion)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 (penetration with minimal perfusion)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 (partial perfusion)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 (complete perfusion)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Device Procedural Success</title>
        <description>Device procedural success consisting of the following:
Successful delivery, inflation, deflation and withdrawal of the study balloon
No evidence of vessel perforation, flow limiting dissection (grade C or higher) or reduction in TIMI flow from baseline related to the study balloon
Final TIMI flow grade of 3 at the conclusion of the PCI procedure</description>
        <time_frame>Peri-procedural (at Day 0)</time_frame>
        <population>Analysis population consists of intent-to-treat subject population.</population>
        <group_list>
          <group group_id="O1">
            <title>Sapphire II PRO</title>
            <description>Single arm with investigational Sapphire II PRO 1.0 and 1.25 mm PTCA dilatation catheters</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Device Procedural Success</title>
          <description>Device procedural success consisting of the following:
Successful delivery, inflation, deflation and withdrawal of the study balloon
No evidence of vessel perforation, flow limiting dissection (grade C or higher) or reduction in TIMI flow from baseline related to the study balloon
Final TIMI flow grade of 3 at the conclusion of the PCI procedure</description>
          <population>Analysis population consists of intent-to-treat subject population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With In-hospital Major Adverse Cardiac Events (MACE)</title>
        <description>In-hospital Major Adverse Cardiac Events (MACE)
All death (cardiac and non-cardiac)
Myocardial infarction (MI)
Target Lesion Revascularization (TLR)</description>
        <time_frame>Endpoints will be measured through hospital discharge (expected to be within 24 hours)</time_frame>
        <population>Analysis population consists of intent-to-treat subject population.</population>
        <group_list>
          <group group_id="O1">
            <title>Sapphire II PRO</title>
            <description>Single arm with investigational Sapphire II PRO 1.0 and 1.25 mm PTCA dilatation catheters</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With In-hospital Major Adverse Cardiac Events (MACE)</title>
          <description>In-hospital Major Adverse Cardiac Events (MACE)
All death (cardiac and non-cardiac)
Myocardial infarction (MI)
Target Lesion Revascularization (TLR)</description>
          <population>Analysis population consists of intent-to-treat subject population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With In-hospital Stent Thrombosis (ST) Within the Target Vessel</title>
        <description>In-hospital stent thrombosis (ST) within the target vessel</description>
        <time_frame>Endpoint will be measured through hospital discharge (expected to be within 24 hours)</time_frame>
        <population>Analysis population consists of intent-to-treat subject population.</population>
        <group_list>
          <group group_id="O1">
            <title>Sapphire II PRO</title>
            <description>Single arm with investigational Sapphire II PRO 1.0 and 1.25 mm PTCA dilatation catheters</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With In-hospital Stent Thrombosis (ST) Within the Target Vessel</title>
          <description>In-hospital stent thrombosis (ST) within the target vessel</description>
          <population>Analysis population consists of intent-to-treat subject population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Significant Arrhythmias (Requiring Intervention)</title>
        <description>Clinically Significant Arrhythmias (requiring intervention)</description>
        <time_frame>Endpoint will be measured through hospital discharge (expected to be within 24 hours)</time_frame>
        <population>Analysis population consists of intent-to-treat subject population.</population>
        <group_list>
          <group group_id="O1">
            <title>Sapphire II PRO</title>
            <description>Single arm with investigational Sapphire II PRO 1.0 and 1.25 mm PTCA dilatation catheters</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Arrhythmias (Requiring Intervention)</title>
          <description>Clinically Significant Arrhythmias (requiring intervention)</description>
          <population>Analysis population consists of intent-to-treat subject population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Per the protocol, adverse events were collected from the point of subject enrollment through study completion at hospital discharge (hospital stay expected to be an average of 24 hours).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Sapphire II PRO</title>
          <description>Single arm with investigational Sapphire II PRO 1.0 and 1.25 mm PTCA dilatation catheters</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Debbie Morrell, Clinical Research Manager</name_or_title>
      <organization>OrbusNeich</organization>
      <phone>954-730-0711</phone>
      <email>DMorrell@OrbusNeich.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

